Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06619847 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy
A Phase 2 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 367
- Enrollment target
NCT06619847 is a Phase 2 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 367 participants.
The verdict
NCT06619847, a Phase 2 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 367 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of VX-993 in treating acute pain after a bunionectomy.
Interventions
- DRUG VX-993
- DRUG Placebo (matched to VX-993)
- DRUG HB/APAP
- DRUG Placebo (matched to HB/APAP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 367 participants |
| Start Date | 2024-10-29 |
| Est. Completion | 2025-05-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06619847
The ClinicalTrials.gov registry entry for NCT06619847 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 367 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which VX-993 is the first listed.
NCT06619847 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06619847 about?
NCT06619847 is a clinical study titled "A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy". The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of VX-993 in treating acute pain after a bunionectomy.
What is the current status of trial NCT06619847?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 367 participants. The study started on 2024-10-29. Estimated completion is 2025-05-27.
What interventions are being tested in trial NCT06619847?
The interventions under investigation include: VX-993 (DRUG), Placebo (matched to VX-993) (DRUG), HB/APAP (DRUG), Placebo (matched to HB/APAP) (DRUG).
Who is sponsoring clinical trial NCT06619847?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.